#USA #New York #Class Action #Levi & Korsinsky #Actinium Pharmaceuticals

Actinium Pharmaceuticals Class Action Lawsuit

Investors in Actinium Pharmaceuticals, Inc. are encouraged to look into a class action lawsuit concerning recent setbacks reported by the company. This legal action, spearheaded by Levi & Korsinsky, LLP, aims to help affected shareholders recover their losses from investments made between October 31, 2022, and August 2, 2024.

Background of the Case

The class action arises due to allegations of securities fraud articulated in the filed complaint against Actinium Pharmaceuticals (NYSE: ATNM). Within this timeframe, the company’s misrepresentation regarding the data from its Phase 3 Sierra trial has raised significant concerns. The complaint points out misleading statements and omissions concerning the FDA’s acceptance and approval processes for the company’s targeted radiotherapy, Iomab-B BLA (Biologics License Application).

Key accusations suggest that:
1. The data from the trial was unlikely to align with FDA guidelines for approval.
2. Additional analyses that Actinium submitted were inadequately demonstrating improvement in overall survival, casting doubt on their validity.
3. Consequently, the FDA might refuse to proceed with a review of Iomab-B, or reject the submission entirely.
4. These issues indicate that statements from company executives concerning its business outlook and operations were unfounded and potentially misleading.

Importance of Legal Action

For shareholders who may have suffered losses, joining this class action is critical. The deadline to apply for lead plaintiff status is May 27, 2025, yet participation does not necessitate taking on this title to potentially receive a share of any recovery from the lawsuit.

Individuals interested in participating may contact Levi & Korsinsky directly via email or telephone to receive guidance on the process. One significant advantage of this action is that there are no costs for class members, meaning qualified investors can participate without incurring out-of-pocket expenses.

Why Levi & Korsinsky?

With over two decades of experience, Levi & Korsinsky has successfully recovered hundreds of millions of dollars for distressed shareholders. Their strong track record in navigating complex securities litigation speaks to their capabilities in high-stakes legal environments. They are recognized as one of the top securities litigation firms in the United States, consistently ranking in the ISS Securities Class Action Services' Top 50 Report.

How to Take Action

If you believe you are eligible and have incurred financial losses due to your investment in Actinium Pharmaceuticals, it is essential to act promptly. You can fill out the lawsuit submission form or reach out to Levi & Korsinsky to learn more about your rights and the potential for recovery.

The law firm is committed to guiding investors through the legal process, ensuring they understand their possible entitlements and the next steps to take. By joining this class action lawsuit, investors can stand together and enhance their chances of financial recovery against the alleged fraudulent activities of Actinium Pharmaceuticals.

Conclusion

Actinium Pharmaceuticals' situation exemplifies the risks involved with investing in the biotechnology sector. Shareholders should remain vigilant in understanding their rights and the implications of alleged corporate misconduct. Joining a class action lawsuit may provide a viable pathway for recovering lost investments, and Levi & Korsinsky is available to assist you with your claims.

For further information, reach out to Levi & Korsinsky, LLP:

• - Email: [email protected]
• - Phone: (212) 363-7500

Make sure your voice is heard and consider your options for recovery in these uncertain times.